Lv53
1600 积分 2025-03-26 加入
Toxicologic Pathology Forum*: Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist’s Dilemma
1个月前
已关闭
Subcutaneous delivery of monoclonal antibodies: How do we get there?
1个月前
已完结
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
1个月前
已完结
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
1个月前
已完结
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
2个月前
已完结
Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs
2个月前
已完结
Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis
2个月前
已完结
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
2个月前
已完结
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
5个月前
已完结
皖公网安备34019202002308
